Showing 1151-1160 of 3017 results for "".
Topical Toxins: Now and Later
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/topical-toxins-now-and-later/18768/Topical neurotoxins are in late-stage development, with the potential to offer "softer" results and reduction of fine wrinkles. But they may not be approved for another few years. In the meantime, micro channel delivery of toxins, such as with AquaGold, is an option. Joel Schlessinger, MD, founder oPain-free Dermatology: Minimizing Discomfort in Procedures for Children and Adults
https://practicaldermatology.com/topics/general-topics/pain-free-dermatology-minimizing-discomfort-in-procedures-for-children-and-adults/21000/It may be useful to review some of the techniques and approaches used to minimize pain.Starting a Practice: Choosing Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/starting-a-practice-choosing-devices/18900/In his new series for Modern Aesthetics® Magazine, Christopher Khorsandi, MD offers tips for aesthetic physicians opening or expanding a practice. In this edition he discusses device selection and integration with an emphasis on marketing and patient conversion.Vehicle Innovations: Experts Discuss What's New
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vehicle-innovations-experts-discuss-what-s-new/18915/Peter Lio, MD and Elaine Siegfried, MD discuss recent innovations in the science behind new vehicles and how these innovations improve treatment, as well as what may hinder some patients' access to these new vehicles. They also offer tips on treatment action plans for atopic patients.Unwinding Psoriasis Comorbidities
https://practicaldermatology.com/topics/psoriasis/unwinding-psoriasis-comorbidities/18936/Ronald Prussick, MD assesses the state of psoriasis treatment, with a particular focus on comorbidities. He also sums up new pivotal data on comborbitities that may shift the treatment spectrum.Systemic Effects of UV Radiation: The Case for Apoptosis of Peripheral Blood Mononuclear Cells
https://practicaldermatology.com/topics/general-topics/PD0709_11-php/22806/Mechanisms of UV-mediated tumorigenesis and development are not fully understood. Findings suggest apoptosis of peripheral blood mononuclear cells may play a role.Topical Rejuvenation Options for the Hyperpigmentation Patient
https://practicaldermatology.com/topics/general-topics/PD0609_03-php/22812/Appropriate rejuvenation regimens can actually correct hyperpigmentation and not make it worse.How to Integrate Physician-Dispensed Products
https://practicaldermatology.com/topics/general-topics/PD0609_10-php/22819/With the correct protocols, staff training, and product selection, physician dispensing can help retain your current patient base and assist in marketing to new patients.You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. R